Researchers developed the compact GAD67 promoter (cmGAD67), which enables selective gene expression in inhibitory neurons. AAV-mediated GAD65 delivery suppressed seizures in multiple mouse models of epilepsy, establishing a promising platform for gene therapy of drug-resistant epilepsy and related neurological disorders.